Story
Craneware Shares Plummet After Slashing Growth Forecast

Summary
Shares of the healthcare software provider fell by over 24% after it reported flat annual recurring revenue and reset its guidance, signaling no revenue growth for the upcoming fiscal year.
Shares in Craneware plc (CRW) plunged more than 24% on Thursday after the healthcare software firm released disappointing full-year results and issued a stark revision to its forward guidance, signaling a halt to near-term growth.
Guidance Reset Shocks Investors
The sharp sell-off was triggered by the company's bleak outlook for fiscal year 2027. Craneware's board reset revenue expectations to align with current annual recurring revenue (ARR) levels of approximately $185 million, effectively forecasting zero growth for the upcoming year. A return to revenue growth is not anticipated until FY28 or beyond, a dramatic shift from the double-digit growth investors had previously expected.
The stock fell to 1,018.5p, hitting a new 52-week low during the session. The decline was entirely company-specific, occurring on a day when broader market indices were trading higher.
Stagnant Results and Operational Headwinds
The bleak forecast accompanied audited results for the year ended June 30, 2026, which showed a significant deceleration in performance. Key figures from the report include:
Ad- Revenue: $206.0 million, nearly flat from $205.7 million in the prior year.
- Adjusted EBITDA: $67.1 million, a modest 3% increase.
- Annual Recurring Revenue (ARR): Held flat at $185 million.
- Net Revenue Retention: Fell to 100% from 107% a year earlier.
Craneware attributed the stalled momentum to operational pressures and anticipated regulatory changes impacting the U.S. 340B drug-pricing program. The company also noted that a cybersecurity incident identified on July 20, 2026, while not disrupting customer services, contributed to a decision to defer significant enterprise contracts into future periods.
Market Reaction and Context
Investors reacted swiftly to the removal of near-term growth from the investment case. The stock is now trading more than 59% below its 52-week high, underscoring a dramatic shift in sentiment.
While the company maintained its dividend and completed a $25 million share buyback program, these shareholder-friendly actions did little to offset the severity of the guidance cut. The market appears to be repricing Craneware from a high-growth software-as-a-service (SaaS) business to a company in a holding pattern, as challenges in its key markets cloud the immediate outlook.
Read next
More on Stocks
AI-Driven 'Tech Titans' Stock Strategy Posts 201% Return, Outpacing S&P 500
An AI-powered stock selection strategy focused on technology companies has generated a total return of over 201% since its launch in late 2023, significantly outperforming the S&P 500, according to data from Investing.com.

Novo Nordisk Shares Tumble After 2030 Growth Targets Signal Slowdown
Shares of the Danish drugmaker fell sharply after it projected its revenue growth from 2026 to 2030 would be 'in line with industry peers,' disappointing investors who had anticipated a more aggressive outlook.

Newag Stock Surges After Q2 Profit Nearly Doubles
Shares of Polish rolling stock manufacturer Newag jumped after the company reported a near-doubling of its second-quarter net profit, supported by a rapidly growing order book and a record-setting day on the Warsaw Stock Exchange.

Critical Metals Shares Surge on US-Denmark Greenland Security Deal
Shares of Critical Metals Corp. jumped over 25% in premarket trading following a U.S. announcement of a security agreement with Denmark concerning Greenland, where the company owns a rare earth project.